Immunopathogenic mechanisms of dry eye disease
Immunopathogenic mechanisms of dry eye disease
批准号:
10197402
负责人:
Reza Dana
金额:
$12.49万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2024-11-30
关键词:
AdultAgeAge related macular degenerationAgingAmericanAntigen-Presenting CellsBlindnessCaringCellsChronicCorneal UlcerDataDesiccationDevelopmentDiagnosisDirect CostsDiseaseDoseElementsEpithelialEpitheliumExposure toEyeEye diseasesFinancial HardshipFunctional disorderGFI1 geneGenerationsHealthcare SystemsHigh PrevalenceHomeostasisHomingImmuneImmunityImmunologic MemoryImpairmentIn VitroInflammationInflammatoryInterferon Type IIInterleukin-17Interleukin-2Interleukin-7Knockout MiceKnowledgeLaboratoriesMaintenanceMediatingMemoryMolecularMusOphthalmologyPathogenicityPatientsPhenotypePrevalencePrincipal InvestigatorProcessRegulationRegulatory T-LymphocyteResearchRiskSeriesSeveritiesSeverity of illnessSourceStressSubstance PVisitVisualWorkagedbasecorneal scarcytokineeffective therapyexperimental studyeye drynessfunctional restorationimprovedin vivoinsightinterleukin-23novelocular surfaceproductivity losspromoterresponserestorationtherapeutic targettraffickingtranscription factortranslational impact
中文摘要
干眼病(DED)是一种慢性免疫介导的眼表疾病,其特征在于
上皮屏障的破坏和持续的眼表炎症,在严重的情况下,
因角膜溃疡和疤痕而失明DED可以说是最常见的眼科疾病
据估计,超过1600万美国成年人因这种疾病而就诊于眼科护理专业人员。
被诊断患有DED(比年龄相关性黄斑变性高出几倍)。特别是
DED的患病率随着年龄的增长而增加。DED给美国医疗保健系统带来的经济负担是巨大的,
生产力损失的直接成本和费用估计每年超过35亿美元。
包括首席研究员在内的几个实验室的工作揭示了关键的见解
关于DED的免疫发病机制。现在有强有力的证据表明,辅助性T细胞-17(Th 17)
是免疫介导的眼表损伤的关键启动子。私家侦探的实验室显示
记忆性Th 17(mTh 17)细胞维持疾病慢性,导致眼表上皮病变,
在暴露于干燥胁迫后仍能持续数月。此外,PI实验室的数据显示,
在DED中,调节性T细胞(T细胞)在抑制Th 17应答方面有缺陷。另外,私家侦探的实验室
已经确定了控制抗原呈递细胞(APC)激活和运输的关键机制,
DED以及效应子Th 17引发、扩增和归巢。尽管在解开
潜在的免疫病理机制,重要的问题仍然没有答案。
我们假设:(1)慢性DED的特征是长期损害的功能,
调节性T细胞(TCFs)通常维持免疫静止,(2)老年人更多
易受DED的影响,这是由于较大的存储器池Th 17,其功能不受老化的调节
你好该项目的主要目标是(i)精确定义表型变化,
表征,以及促进DED中长期Treg功能障碍的机制;(ii)确定
mTh 17细胞的细胞前体,以及影响mTh 17细胞生成的细胞因子机制。
免疫记忆;和(iii)定义的因素,放大mTh 17免疫老化。实现这些
目标,三个具体的目标已经确定,以回答以下问题:目标1:什么是
DED中持续Treg功能障碍的致病机制?目的2:哪些效应子Th 17亚群是
倾向于进入内存池(从而允许DED长期性),什么因素调节这一点
过程?最后,目标3:什么是增强Th 17介导的细胞和分子机制?
在老化中?预计这项研究将产生重大的翻译影响,
DED的患病率,我们对其免疫发病机制的了解仍然有限,
缺乏有效的治疗方法。
英文摘要
Dry eye disease (DED) is a chronic immune-mediated disorder of the ocular surface, characterized by
disruption of the epithelial barrier and sustained ocular surface inflammation, which in severe cases results
in blindness from corneal ulceration and scarring. DED is arguably the most common ophthalmologic
condition for which patients visit eye care professionals, with more than 16 million US adults estimated to
have been diagnosed with DED (several folds higher than age-related macular degeneration). Notably, the
prevalence of DED increases with age. The financial burden of DED to the US healthcare system is vast,
with direct costs and expenses from productivity losses estimated to exceed $3.5 billion annually.
The work of several laboratories, including the Principal Investigator's, has revealed key insights
concerning the immunopathogenesis of DED. There is now strong evidence that T helper-17 (Th17) cells
are critical promoters of immune-mediated damage to the ocular surface. The PI's laboratory has shown
that memory Th17 (mTh17) cells maintain disease chronicity, resulting in ocular surface epitheliopathy that
persists for many months after exposure to desiccating stress. Moreover, data from the PI's lab show that
regulatory T cells (Tregs) are defective in suppressing the Th17 response in DED. In addition, the PI's lab
has identified critical mechanisms controlling antigen-presenting cell (APC) activation and trafficking in
DED, as well as effector Th17 priming, expansion and homing. Despite substantial progress in unraveling
underlying immunopathogenic mechanisms, important questions remain unanswered.
We hypothesize that (1) chronic DED is characterized by long-term impairment in the function of
regulatory T cells (Tregs) that normally maintain immune quiescence, and that (2) the aged are more
susceptible to DED due to a larger pool of memory Th17, whose function is inadequately regulated by aged
Tregs. The principal objectives of this project are to (i) precisely define the phenotypic changes that
characterize, and the mechanisms that promote long-term Treg dysfunction in DED; (ii) determine the
cellular precursors of mTh17 cells, as well as the cytokine mechanisms that influence the generation of
immunologic memory; and (iii) define the factors that amplify mTh17 immunity in aging. To achieve these
objectives, three specific aims have been defined to answer the following questions: Aim 1: What are the
causative mechanisms of enduring Treg dysfunction in DED? Aim 2: Which effector Th17 subsets are
predisposed to enter the memory pool (thus permitting DED chronicity), and what factors regulate this
process? And finally Aim 3: What are the cellular and molecular mechanisms that augment Th17-mediated
DED in aging? It is anticipated that this research will have significant translational impact given the high
prevalence of DED, the still limited knowledge we have regarding its immunopathogenesis, and the relative
scarcity of effective treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Impact of Donor Diabetes on Corneal Immune Cells and Graft Survival
-
批准号:10707166
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2022
-
负责人:Reza Dana
-
依托单位:
Therapeutic Function of alpha-Melanocyte Stimulating Hormone (α-MSH) in Acute Injury and Chronic Degeneration of Corneal Endothelium
-
批准号:10394920
-
项目类别:
-
资助金额:$23.89万
-
财政年份:2021
-
负责人:Reza Dana
-
依托单位:
Therapeutic Function of alpha-Melanocyte Stimulating Hormone (α-MSH) in Acute Injury and Chronic Degeneration of Corneal Endothelium
-
批准号:10191281
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2021
-
负责人:Reza Dana
-
依托单位:
Efficacy of the Neuropeptide Alpha-Melanocyte Stimulating Hormone (α-MSH) in Promoting Survival of Corneal Endothelial Cells in Eye Banking and Transplantation
-
批准号:9762115
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2018
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:8539627
-
项目类别:
-
资助金额:$39.81万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:7949195
-
项目类别:
-
资助金额:$43.84万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:8328689
-
项目类别:
-
资助金额:$41.9万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:9129776
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:10524044
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:9884617
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:8139780
-
项目类别:
-
资助金额:$41.9万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:10063525
-
项目类别:
-
资助金额:$47.77万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:8928621
-
项目类别:
-
资助金额:$48.27万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:9321030
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:8692069
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
Immunopathogenic mechanisms of dry eye disease
-
批准号:10312003
-
项目类别:
-
资助金额:$47.77万
-
财政年份:2010
-
负责人:Reza Dana
-
依托单位:
New Strategies for Modulation of Corneal and Ocular Surface Inflammation
-
批准号:7685378
-
项目类别:
-
资助金额:$11.88万
-
财政年份:2008
-
负责人:Reza Dana
-
依托单位:
New Strategies for Modulation of Corneal and Ocular Surface Inflammation
-
批准号:8330890
-
项目类别:
-
资助金额:$11.88万
-
财政年份:2008
-
负责人:Reza Dana
-
依托单位:
New Strategies for Modulation of Corneal and Ocular Surface Inflammation
-
批准号:8133828
-
项目类别:
-
资助金额:$11.88万
-
财政年份:2008
-
负责人:Reza Dana
-
依托单位:
New Strategies for Modulation of Corneal and Ocular Surface Inflammation
-
批准号:7513469
-
项目类别:
-
资助金额:$11.88万
-
财政年份:2008
-
负责人:Reza Dana
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: